Cystic fibrosis related diabetes: Medical management

被引:23
|
作者
Ode, Katie Larson [1 ,2 ]
Chan, Christine L. [3 ,4 ]
Granados, Andrea [5 ]
Moheet, Amir [6 ]
Moran, Antoinette [7 ]
Brennan, Amanda L. [8 ]
机构
[1] Univ Iowa, Dept Pediat, Stead Family Childrens Hosp, Iowa City, IA 52242 USA
[2] Univ Iowa, Fraternal Order Eagles Diabet Res Ctr, Iowa City, IA 52242 USA
[3] Univ Colorado, Childrens Hosp Colorado, Aurora, CO USA
[4] Barbara Davis Ctr Childhood Diabet, Aurora, CO USA
[5] Washington Univ, Dept Pediat, Sch Med St Louis, St Louis, MO 63130 USA
[6] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA
[7] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA
[8] Univ Hosp South Manchester, Manchester Adult Cyst Fibrosis Ctr, Manchester, Lancs, England
关键词
Cystic fibrosis; Cystic fibrosis related diabetes mellitus; Insulin; Treatment; Oral hypoglycaemic agents; Insulin pump;
D O I
10.1016/j.jcf.2019.08.003
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Cystic Fibrosis Related Diabetes Mellitus (CFRD) drives excess pulmonary morbidity and mortality in patients with cystic fibrosis (CF). The recommended treatment is insulin therapy. Insulin therapy in CF should be customized to the specific patient. CF patients typically require intensive insulin regimens such as multiple daily injections or insulin pump therapy, but frequently require lower doses than in type 1 diabetes mellitus. Patients with CF may also need insulin to cover intravenous or enteral feedings. Pre-diabetic glycaemic abnormalities are also associated with clinical decline in cystic fibrosis prior to the diagnosis of CFRD, however, whether and how this should be treated is not fully determined. There is also interest, but inadequate data regarding other treatments besides insulin (i.e., oral medications) for treatment of pre-diabetes or CFRD. CFTR potentiator and corrector therapy has yet to demonstrate an effect on the rate of CFRD, but may improve insulin secretion. There is great opportunity for further research to better understand when and how best to treat glycaemic abnormalities in cystic fibrosis. (C) 2019 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.
引用
收藏
页码:S10 / S18
页数:9
相关论文
共 50 条
  • [1] Management of cystic fibrosis-related diabetes
    O'Riordan, Stephen M. P.
    Robinson, Paul D.
    Donaghue, Kim C.
    Moran, Antoinette
    [J]. PEDIATRIC DIABETES, 2008, 9 (04) : 338 - 344
  • [2] The diagnosis and management of cystic fibrosis related diabetes
    Hardin, DS
    [J]. ENDOCRINOLOGIST, 1998, 8 (04): : 265 - 272
  • [3] Management of cystic fibrosis related diabetes in the UK
    Mohan, K.
    Dyce, P.
    Miller, H.
    Ledson, M. J.
    Walshaw, M. J.
    [J]. THORAX, 2007, 62 : A103 - A103
  • [4] Pharmacological management of cystic fibrosis related diabetes
    Moheet, Amir
    Moran, Antoinette
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (02) : 185 - 191
  • [5] Nutritional management of cystic fibrosis and cystic fibrosis-related diabetes in Australia
    McFarlane, Catherine
    Marshall, Katrina
    Doola, Ra'eesa
    Todd, Alwyn
    [J]. NUTRITION & DIETETICS, 2016, 73 (04) : 376 - 382
  • [6] Management of cystic fibrosis related diabetes: A survey of UK cystic fibrosis centers
    Mohan, Kamlesh
    Miller, Helen
    Burhan, Hassan
    Ledson, Martin J.
    Walshaw, Martin J.
    [J]. PEDIATRIC PULMONOLOGY, 2008, 43 (07) : 642 - 647
  • [7] Advances in the detection and management of cystic fibrosis related diabetes
    Hameed, Shihab
    Jaffe, Adam
    Verge, Charles F.
    [J]. CURRENT OPINION IN PEDIATRICS, 2015, 27 (04) : 525 - 533
  • [8] Cystic fibrosis related diabetes
    Zirbes, Jacquelyn
    Milla, Carlos E.
    [J]. PAEDIATRIC RESPIRATORY REVIEWS, 2009, 10 (03) : 118 - 123
  • [9] Cystic Fibrosis Related Diabetes
    Donal O’Shea
    Jean O’Connell
    [J]. Current Diabetes Reports, 2014, 14
  • [10] Cystic Fibrosis Related Diabetes
    O'Shea, Donal
    O'Connell, Jean
    [J]. CURRENT DIABETES REPORTS, 2014, 14 (08)